FDA OKs Merck KEYTRUDA as Adjuvant for Certain Renal Cell Carcinomas

KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions

KEYTRUDA Is the First Immunotherapy Approved for the Adjuvant Treatment of These Patients With RCC

https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-114500052.html